View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule...

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., March 06, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on March 3, 2026 to three new employees under Pacira’s Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee’s entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), ...

 PRESS RELEASE

Nasdaq Reports February 2026 Volumes

Nasdaq Reports February 2026 Volumes NEW YORK, March 05, 2026 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today reported monthly volumes for February 2026 on its Investor Relations website. A data sheet showing this information can be found at: .   About Nasdaq  Nasdaq (Nasdaq: NDAQ) is a leading technology platform that powers the world’s economies. We architect the world’s most modern markets, power the innovation economy, and build trust in the financial system. We empower economic opportunity by designing and deploying markets, technology, data, and advanced analytics that enable our c...

 PRESS RELEASE

Nasdaq Texas Launches with Inaugural Dual Listings

Nasdaq Texas Launches with Inaugural Dual Listings Nasdaq Texas Celebrates Official Launch with the Nasdaq Stock Market Closing Bell at the Alamo with the First Cohort of Dual Listings Nasdaq, Inc. to Dual List on Nasdaq Texas Alongside Inaugural Group SAN ANTONIO, March 05, 2026 (GLOBE NEWSWIRE) -- Nasdaq Texas will mark another milestone by ringing the Nasdaq Closing Bell at The Alamo, San Antonio, Texas, commemorating the 190th anniversary of the Battle of the Alamo and the full operational launch of Nasdaq Texas following approval of its listing rules from the U.S. Securities and Ex...

 PRESS RELEASE

Pacira BioSciences to Participate in Fireside Chat at the Barclays 28t...

Pacira BioSciences to Participate in Fireside Chat at the Barclays 28th Annual Global Healthcare Conference BRISBANE, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will participate in an analyst-led fireside chat at the Barclays 28th Annual Global Healthcare Conference at 2:30 PM ET on Wednesday, March 11, 2026 in Miami. Live audio of the event can be accessed by visiting the “Events” page of the company’s ...

 PRESS RELEASE

Pacira BioSciences Presents Two Real-World Studies from Its Innovation...

Pacira BioSciences Presents Two Real-World Studies from Its Innovations in Genicular Outcomes Registry (IGOR) -- Studies highlight the clinical effectiveness of EXPAREL for total knee arthroplasty and long-term pain management with ioveraº for patients with osteoarthritis (OA) of the knee -- -- Data presented at the American Academy of Orthopedic Surgeons 2026 Annual Meeting -- BRISBANE, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of p...

Wedbush Research
  • Wedbush Research
W WAYFAIR INC.
UBI UBISOFT ENTERTAINMENT SA
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
WDC WESTERN DIGITAL CORPORATION
VYGR VOYAGER THERAPEUTICS INC.
TTWO TAKE-TWO INTERACTIVE SOFTWARE INC.
TRIP TRIPADVISOR INC.
SRPT SAREPTA THERAPEUTICS INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
RARE ULTRAGENYX PHARMACEUTICAL INC.
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NVCR NOVOCURE LTD.
NTAP NETAPP INC.
NBIX NEUROCRINE BIOSCIENCES INC.
MU MICRON TECHNOLOGY INC.
MELI MERCADOLIBRE INC.
KURA KURA ONCOLOGY INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
GERN GERON CORP.
FB FACEBOOK INC. CLASS A
FATE FATE THERAPEUTICS INC
EXPE EXPEDIA GROUP INC.
ETSY ETSY INC.
EBAY EBAY INC.
CTMX CYTOMX THERAPEUTICS INC.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
BCRX BIOCRYST PHARMACEUTICALS INC.
AXTI AXT INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
CDR CD PROJEKT S.A.
FRX_CN FENNEC PHARMACEUTICALS
7974 NINTENDO CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
EA ELECTRONIC ARTS INC.
PTGX PROTAGONIST THERAPEUTICS
ANAB ANAPTYSBIO INC.
ARGX ARGENX ADS
OVID OVID THERAPEUTICS
ISR ISORAY
SE SEA ADS
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
APLS APELLIS PHARMACEUTICALS
BKNG BOOKING HOLDINGS INC.
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
STRO SUTRO BIOPHARMA
LYFT LYFT
PINS PINTEREST INC. CLASS A
UBER UBER TECHNOLOGIES INC.
CHWY CHEWY INC. CLASS A
STOK STOKE THERAPEUTICS
SMCI SUPER MICRO COMPUTER
IDYA INC.
PASG IDEAYA BIOSCIENCES
BDTX PASSAGE BIO
ACET BLACK DIAMOND THERAPEUTICS
KROS ADICET BIO INC
ZNTL KEROS THERAPEUTICS
BEAM ZENTALIS PHARMACEUTICALS
LRMR BEAM THERAPEUTICS
OCUP LARIMAR THERAPEUTICS INC
PRAX OCUPHIRE PHARMA INC
COGT PRAXIS PRECISION MEDICINES
U COGENT BIOSCIENCES INC
TVTX UNITY SOFTWARE
DASH TRAVERE THERAPEUTICS INC
ABNB DOORDASH
VRDN AIRBNB INC. CLASS A
PLTK VIRIDIAN THERAPEUTICS INC
NUVB PLAYTIKA HOLDING
RBLX NUVATION BIO INC (A)
DAWN ROBLOX
TNGX DAY ONE BIOPHARMACEUTICALS INC
STX TANGO THERAPEUTICS
HOWL INC
APP SEAGATE TECHNOLOGY HLDGS PLC
TTD WEREWOLF THERAPEUTICS INC
QUBT APPLOVIN CORP
GFS THE TRADE DESK
GMTX INC.
TYRA QUANTUM COMPUTING INC
EWTX GLOBALFOUNDRIES INC
SLDB GEMINI THERAPEUTICS INC
DDI TYRA BIOSCIENCES INC
APGE EDGEWISE THERAPEUTICS INC
EMBRAC B SOLID BIOSCIENCES INC
DNTH DOUBLEDOWN INTERACTIVE CO LTD
CART APOGEE THERAPEUTICS INC
NATL EMBRACER GROUP AB
CGON DIANTHUS THERAPEUTICS INC
ORKA MAPLEBEAR INC.
BCAX NCR ATLEOS CORPORATION
ZBIO CG ONCOLOGY INC
TLX ORUKA THERAPEUTICS INC
MAZE BICARA THERAPEUTICS INC.
JBIO ZENAS BIOPHARMA INC.
TELIX PHARMACEUTICALS LIMITED
MAZE THERAPEUTICS INC
JADE BIOSCIENCES INC
Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: February 28, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Nasdaq Executives to Present at Upcoming Investor Conferences

Nasdaq Executives to Present at Upcoming Investor Conferences NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) will be presenting at the following conferences in March with webcasts available at Nasdaq’s Investor Relations website: . Who:Sarah Youngwood, Executive Vice President & Chief Financial Officer, NasdaqWhat:Morgan Stanley Technology, Media & Telecom ConferenceWhen:Monday, March 2nd, 11:30 AM ET  Who:Jeremy Skule, Executive Vice President, Chief Strategy Officer & Executive Chair, Financial Crime Management Technology, NasdaqWhat:Raymond James 47thAnnual Instituti...

 PRESS RELEASE

Pacira BioSciences Reports Fourth Quarter and Full-Year 2025 Financial...

Pacira BioSciences Reports Fourth Quarter and Full-Year 2025 Financial Results — Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three years — — Conference call today at 4:30 p.m. ET — BRISBANE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today reported financial results for the fourth quarter and full-year of 2025. “2025 was a year of disciplined execution for P...

 PRESS RELEASE

Nasdaq Announces Mid-Month Open Short Interest Positions in Nasdaq Sto...

Nasdaq Announces Mid-Month Open Short Interest Positions in Nasdaq Stocks as of Settlement Date February 13, 2026 NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- At the end of the settlement date of February 13, 2026, short interest in 3,595 Nasdaq Global MarketSM securities totaled 15,834,216,597 shares compared with 15,574,683,465 shares in 3,547 Global Market issues reported for the prior settlement date of January 30, 2026. The mid-January short interest represents 2.25 days compared with 2.58 days for the prior reporting period. Short interest in 1,654 securities on The Nasdaq Capital M...

 PRESS RELEASE

Nasdaq Raises Medium‑Term Revenue Outlook and Outlines Strategy for It...

Nasdaq Raises Medium‑Term Revenue Outlook and Outlines Strategy for Its Next Phase of Scalable Growth at 2026 Investor Day Nasdaq raises medium-term Solutions revenue outlook to 9-12% growthMaintains medium-term outlook for expense growth of 5-8%Company reinforces its position as trusted transformation partner in the AI eraCommits to actioning AI productivity program with an expense efficiency target of $100 million by 2027 NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today will host its Investor Day at 8:00 a.m. ET, where Adena Friedman, Nasdaq Chair and CEO, Sarah ...

American Assets Trust Inc: 1 director

A director at American Assets Trust Inc bought 82,386 shares at 19.417USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two y...

 PRESS RELEASE

HP Inc. Reports Fiscal 2026 First Quarter Results

HP Inc. Reports Fiscal 2026 First Quarter Results PALO ALTO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- HP (NYSE: HPQ) First quarter GAAP diluted net earnings per share ("EPS") of $0.58, down 1.7% from the prior year period First quarter non-GAAP diluted net EPS of $0.81, up 9.5% from the prior year period First quarter net revenue of $14.4 billion, up 6.9% from the prior-year period First quarter net cash provided by operating activities of $383 million, free cash flow of $175 million First quarter returned $0.6 billion to shareholders in the form of share repurchases and dividends ...

Moody's Ratings announces completion of a periodic review of ratings o...

Moody's Ratings (Moody's) has completed a periodic review of the ratings of Nasdaq, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 18 February 2026 in which we reassessed the appropriateness of the ratings in the context of t...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: February 21, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: February 20, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

MSCI Inc: 1 director

A director at MSCI Inc bought 3,681 shares at 543.210USD and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...

Janus Henderson Group Plc: 1 director

A director at Janus Henderson Group Plc sold/sold after exercising options 22,000 shares at 49.271USD and the significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's d...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch